Cannabis and Medical Benefits: New Research Raises Questions

Cannabis has long been linked with various medical advantages, but some recent studies are beginning to challenge that notion.

A significant analysis published in JAMA examined over 2,500 scientific papers from the last fifteen years, including reviews, clinical trials, and guidelines regarding medical cannabis use.

According to Dr. Michael Hsu of UCLA Health Sciences, one of the study’s authors, “Many people are turning to cannabis for relief, but our study reveals a substantial disconnect between public belief and scientific evidence surrounding its efficacy for most medical conditions.”

Researchers, primarily from UCLA but also including professionals from esteemed institutions such as Harvard and NYU, aimed to evaluate the strength of the existing research on medical cannabis and provide evidence-based guidance for clinicians.

The review indicated that the evidence backing most medical uses of cannabis and cannabinoids is either limited or insufficient. There aren’t many conditions where cannabinoid therapy demonstrates clear effectiveness supported by robust clinical data.

However, the analysis showed stronger evidence for certain FDA-approved cannabinoid medications, which appear effective in treating specific conditions like HIV/AIDS-related anorexia, chemotherapy-induced nausea, and some severe childhood seizure disorders.

On the safety side, the review raised alarms about the mental health risks linked to potent cannabis use, especially among young users. The use of strong cannabis was associated with heightened rates of anxiety disorders and psychotic symptoms.

Additionally, daily use of inhaled cannabis corresponded with increased risks of cardiovascular issues, including coronary heart disease and strokes, when compared to non-daily use.

Researchers emphasized the need for clinicians to balance potential benefits against known risks when discussing cannabis with patients. They suggested that doctors perform thorough assessments, including screening for cardiovascular risk and evaluating mental health histories.

Open, genuine discussions about the role of cannabis in medical treatment are essential. “Patients should have honest conversations about what science tells us—and doesn’t tell us—about medical cannabis,” Hsu noted.

Nonetheless, the paper is characterized as narrative rather than a systematic review, which means that it didn’t adhere to standardized approaches that help eliminate bias in study selection and evaluation.

Furthermore, the review pointed out that some evidence originates from observational studies instead of randomized trials, complicating the ability to establish direct cause-and-effect relationships. The findings may also not be universally applicable across different populations, products, or dosages.